Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Next-generation LMP2A-targeting TCR-recombinant T cells with inducible IL-18 expression to treat EBV-associated malignancies.

Molecular therapy. Oncology·2026
Same author

Septin7 is essential in early hematopoiesis, but redundant at later stages.

Life science alliance·2026
Same author

The German National Strategy for Gene- and Cell-Based Therapies: Generating Impact by Employing a Novel Multi-Stakeholder Approach.

Human gene therapy·2026
Same author

Capsid-engineered AAV vector overcomes a key intracellular barrier and efficiently transduces spiral ganglion neurons in adult mice.

Molecular therapy. Advances·2026
Same author

Editorial: Community Series in Engineered Immune Cells in Cancer Immunotherapy (EICCI), volume II.

Frontiers in immunology·2026
Same author

Ex vivo long-term expansion of human hematopoietic stem and progenitor cells as a tool for modeling vector integration sites and clonality.

Journal of translational medicine·2026

Related Experiment Video

Updated: Jul 17, 2026

Lentiviral Vector Preparation for Efficient Gene and MicroRNA Modulation of Peritoneal Cavity Tissue-Resident Macrophages In Vivo in Mice
06:33

Lentiviral Vector Preparation for Efficient Gene and MicroRNA Modulation of Peritoneal Cavity Tissue-Resident Macrophages In Vivo in Mice

Published on: February 16, 2024

Addressing the package: Cell-specific gene delivery using lentiviral vectors.

Anjali Shrivastava1, Felix L Warnecke1, Juliane W Schott1

  • 1Institute of Experimental Hematology, Hannover Medical School, Hannover, 30625, Germany; REBIRTH-Research Center for Translational Regenerative Medicine, Hannover Medical School, Hannover, 30625, Germany.

Molecular Therapy : the Journal of the American Society of Gene Therapy
|July 16, 2026
PubMed
Summary

Bioengineered lentiviral vectors with VSV-G envelopes can be targeted to specific cells, advancing gene therapy. This innovation promises more accessible, faster treatments for various diseases.

More Related Videos

Packaging HIV- or FIV-based Lentivector Expression Constructs & Transduction of VSV-G Pseudotyped Viral Particles
11:08

Packaging HIV- or FIV-based Lentivector Expression Constructs & Transduction of VSV-G Pseudotyped Viral Particles

Published on: April 8, 2012

Lentiviral Vector Platform for the Efficient Delivery of Epigenome-editing Tools into Human Induced Pluripotent Stem Cell-derived Disease Models
13:47

Lentiviral Vector Platform for the Efficient Delivery of Epigenome-editing Tools into Human Induced Pluripotent Stem Cell-derived Disease Models

Published on: March 29, 2019

Related Experiment Videos

Last Updated: Jul 17, 2026

Lentiviral Vector Preparation for Efficient Gene and MicroRNA Modulation of Peritoneal Cavity Tissue-Resident Macrophages In Vivo in Mice
06:33

Lentiviral Vector Preparation for Efficient Gene and MicroRNA Modulation of Peritoneal Cavity Tissue-Resident Macrophages In Vivo in Mice

Published on: February 16, 2024

Packaging HIV- or FIV-based Lentivector Expression Constructs & Transduction of VSV-G Pseudotyped Viral Particles
11:08

Packaging HIV- or FIV-based Lentivector Expression Constructs & Transduction of VSV-G Pseudotyped Viral Particles

Published on: April 8, 2012

Lentiviral Vector Platform for the Efficient Delivery of Epigenome-editing Tools into Human Induced Pluripotent Stem Cell-derived Disease Models
13:47

Lentiviral Vector Platform for the Efficient Delivery of Epigenome-editing Tools into Human Induced Pluripotent Stem Cell-derived Disease Models

Published on: March 29, 2019

Area of Science:

  • Biotechnology
  • Gene Therapy
  • Virology

Background:

  • Lentiviral vectors offer efficient gene delivery to various cell types.
  • Vesicular stomatitis virus glycoprotein (VSV-G) pseudotyping provides broad tropism and particle stability.
  • Current broad tropism limits precise in vivo cell targeting.

Purpose of the Study:

  • To review advances in bioengineering VSV-G-pseudotyped lentiviral vectors for targeted gene delivery.
  • To explore the potential of these targeted vectors in various therapeutic areas.

Main Methods:

  • Structural insights into VSV-G enable receptor-binding modifications.
  • Targeting moieties are incorporated to redirect vectors to specific cell antigens.
  • Bioengineering strategies are employed to enhance vector specificity and function.

Main Results:

  • Targeted lentiviral vectors can be engineered to bind specific cell surface receptors.
  • Modified VSV-G pseudotyped vectors demonstrate redirected tropism.
  • This approach facilitates precise in vivo gene delivery.

Conclusions:

  • Bioengineered VSV-G lentiviral vectors offer precise in vivo targeting capabilities.
  • Targeted lentiviral vectors represent a significant advancement for gene therapy applications.
  • These vectors hold promise for developing 'off-the-shelf' therapies, reducing treatment time and cost.